{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000153","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.076917+00:00","generated_at":"2026-05-18T22:11:58.659451+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT","bullets":["Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).","BAT is used to treat symptomatic botulism from exposure to botulinum neurotoxin serotypes A through G.","Supply supports U.S. government stockpile for military and civilian biodefense preparedness.","Paul Williams, SVP, noted the award reinforces Emergent's role in public health countermeasures."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000153","json":"https://secwatch.observer/filing/0001367644-25-000153.json","markdown":"https://secwatch.observer/filing/0001367644-25-000153.md","text":"https://secwatch.observer/filing/0001367644-25-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000153/0001367644-25-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000153/ebs-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:11:58.659451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}